Elevated coagulation and inflammatory markers in adolescents with a history of premature adrenarche

Metabolism: Clinical and Experimental

Volumn 58, Issue 4, 2009, Pages 576-581

  Livadas, Sarantis ^a   Dracopoulou, Maria ^a   Vasileiadi, Karmen ^a   Lazaropoulou, Christina ^b   Magiakou, Maria Alexandra ^a   Xekouki, Paraskevi ^a   Voutetakis, Antonis ^a   Kanaka Gantenbein, Christina ^a   Papassotiriou, Ioannis ^b   Stefanadis, Christodoulos ^a   Chrousos, George P ^a   Dacou Voutetakis, Catherine ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADOLESCENT; ADRENARCHE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD CLOTTING; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; HYPERANDROGENISM; INFLAMMATION; INSULIN RESISTANCE; OXIDATIVE STRESS; PRECOCIOUS PUBERTY; PRIORITY JOURNAL;

ADOLESCENT; ADRENARCHE; BIOLOGICAL MARKERS; BLOOD COAGULATION; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE;

EID: 62349124075     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2008.12.002     Document Type: Article

References (47)

1. Dacou-Voutetakis C., Livadas S., Voutetakis A., et al. Adrenarche, premature. In: Martini L. (Ed). Encyclopedia of endocrine diseases vol 1 (2004), Elsevier Inc. 99-105
2. Ibanez L., Dimartino-Nardi J., Potau N., et al. Premature adrenarche-normal variant or forerunner of adult disease?. Endocr Rev 21 (2000) 671-696
3. Talbott E.O., Zborowski J.V., Rager J.R., et al. Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. J Clin Endocrinol Metab 89 (2004) 5454-5461
4. Ehrmann D.A., Liljenquist D.R., Kasza K., et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 48-53
5. Kousta E., Tolis G., and Franks S. Polycystic ovary syndrome. Revised diagnostic criteria and long-term health consequences. Hormones (Athens) 4 (2005) 133-147
6. Coviello A.D., Legro R.S., and Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91 (2006) 492-497
7. Haffner S.M. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 92 (2003) 18-26
8. Sinaiko A.R., Steinberger J., Moran A., et al. Relation of body mass index and insulin resistance to cardiovascular risk factors, inflammatory factors and oxidative stress during adolescence. Circulation 111 (2005) 1985-1991
9. Stephens J.W., Gable D.R., Hurel S.J., et al. Increased plasma markers of oxidative stress are associated with coronary heart disease in males with diabetes mellitus and with 10-year risk in a prospective sample of males. Clin Chem 52 (2006) 446-452
10. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 352 (2005) 1685-1695
11. Couillard C., Ruel G., Archer W.R., et al. Circulating levels of oxidative stress markers and endothelial adhesion molecules in men with abdominal obesity. J Clin Endocrinol Metab 90 (2005) 6454-6459
12. Fenkci V., Fenkci S., Yilmazer M., et al. Decreased total antioxidant status and increased oxidative stress in women with polycystic ovary syndrome may contribute to the risk of cardiovascular disease. Fertil Steril 80 (2003) 123-127
13. Sabuncu T., Vural H., Harma M., et al. Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34 (2001) 407-413
14. Gonzalez F., Rote N.S., Minium J., et al. Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91 (2006) 336-340
15. Mertens I., Verrijken A., Michiels J.J., et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 30 (2006) 1308-1314
16. Glueck C.J., Sieve L., Zhu B., et al. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome. Metabolism 55 (2006) 345-352
17. Glueck C.J., Wang P., Fontaine R.N., et al. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism 48 (1999) 1589-1595
18. Orio Jr. F., Palomba S., Cascella T., et al. Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome?. Reprod Biomed Online 9 (2004) 505-510
19. Auchus R.J., and Rainey W.E. Adrenarche-physiology, biochemistry and human disease. Clin Endocrinol (Oxf) 60 (2004) 288-296
20. Chiotis D., Krikos X., Tsiftsis G., et al. Body mass index and prevalence of obesity in subjects of Hellenic origin aged 0-18 years, living in the Athens area. Ann Clin Pediatr Univ Atheniensis 51 (2004) 139-154
21. Tanner J.M., and Whitehouse R.H. Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51 (1976) 170-179
22. Ferriman D., and Gallwey J. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21 (1961) 1440-1447
23. Schimke I., Muller J., Priem F., et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 38 (2001) 178-183
24. Vuguin P., Saenger P., and Dimartino-Nardi J. Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenarche. J Clin Endocrinol Metab 86 (2001) 4618-4621
25. Silfen M.E., Manibo, McMahon D.J., et al. Comparison of simple measures of insulin sensitivity in young girls with premature adrenarche: the fasting glucose to insulin ratio may be a simple and useful measure. J Clin Endocrinol Metab 86 (2001) 2863-2868
26. Ibanez L., Potau N., Chacon P., et al. Hyperinsulinaemia, dyslipaemia and cardiovascular risk in girls with a history of premature pubarche. Diabetologia 41 (1998) 1057-1063
27. Guven A., Cinaz P., and Bideci A. Is premature adrenarche a risk factor for atherogenesis?. Pediatr Int 47 (2005) 20-25
28. Meas T., Chevenne D., Thibaud E., et al. Endocrine consequences of premature pubarche in post-pubertal Caucasian girls. Clin Endocrinol (Oxf) 57 (2002) 101-106
29. Dimartino-Nardi J. Premature adrenarche: findings in prepubertal African-American and Caribbean-Hispanic girls. Acta Paediatr Suppl 88 (1999) 67-72
30. l'Allemand D., Schmidt S., Rousson V., et al. Associations between body mass, leptin, IGF-I and circulating adrenal androgens in children with obesity and premature adrenarche. Eur J Endocrinol 146 (2002) 537-543
31. Zukauskaite S., Seibokaite A., Lasas L., et al. Serum hormone levels and anthropometric characteristics in girls with hyperandrogenism. Medicina (Kaunas) 41 (2005) 305-312
32. Ibanez L., Valls C., and De Zegher F. Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio. Hum Reprod 21 (2006) 451-456
33. Kravariti M., Naka K.K., Kalantaridou S.N., et al. Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 5088-5095
34. Kelly C.C., Lyall H., Petrie J.R., et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86 (2001) 2453-2455
35. Tarkun I., Arslan B.C., Canturk Z., et al. Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation. J Clin Endocrinol Metab 89 (2004) 5592-5596
36. Moran A., Steffen L.M., Jacobs Jr. D.R., et al. Relation of C-reactive protein to insulin resistance and cardiovascular risk factors in youth. Diabetes Care 28 (2005) 1763-1768
37. Diamanti-Kandarakis E., Paterakis T., Alexandraki K., et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 21 (2006) 1426-1431
38. Ibanez L., Valls C., Cabre S., et al. Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism: the key role of early, low-dose flutamide. J Clin Endocrinol Metab 89 (2004) 4716-4720
39. Kwintkiewicz J., Spaczynski R.Z., Foyouzi N., et al. Insulin and oxidative stress modulate proliferation of rat ovarian theca-interstitial cells through diverse signal transduction pathways. Biol Reprod 74 (2006) 1034-1040
40. Dinger Y., Akcay T., Erdem T., et al. DNA damage, DNA susceptibility to oxidation and glutathione level in women with polycystic ovary syndrome. Scand J Clin Lab Invest 65 (2005) 721-728
41. Kelishadi R., Sharifi M., Khosravi A., et al. Relationship between C-reactive protein and atherosclerotic risk factors and oxidative stress markers among young persons 10-18 years old. Clin Chem 53 (2007) 456-464
42. Andiran N., Yordam N., and Kirazli S. Global fibrinolytic capacity is decreased in girls with premature adrenarche: a new pathological finding?. J Pediatr Endocrinol Metab 18 (2005) 1373-1381
43. Ibanez L., Aulesa C., Potau N., et al. Plasminogen activator inhibitor-1 in girls with precocious pubarche: a premenarcheal marker for polycystic ovary syndrome?. Pediatr Res 51 (2002) 244-248
44. Morange P.E., Aubert J., Peiretti F., et al. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 48 (1999) 890-895
45. Mussoni L., Mannucci L., Sirtori M., Camera M., Maderna P., Sironi L., et al. Hypertriglyceridemia and regulation of fibrinolytic activity. Arteriosclerosis and Thrombosis 12 (1992) 19-27
46. Swiatkowska M., Szemraj J., and Cierniewski C.S. Induction of PAI-1 expression by tumor necrosis factor alpha in endothelial cells is mediated by its responsive element located in the 4G/5G site. FEBS J. 272 (2005) 5821-5831
47. Vulin A.I., and Stanley F.M. Oxidative stress activates the plasminogen activator inhibitor type 1 (PAI-1) promoter through an AP-1 response element and cooperates with insulin for additive effects on PAI-1 transcription. J Biol Chem 279 (2004) 25172-25178